このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

筋肉痛脳脊髄炎/慢性疲労症候群(ME/CFS)におけるリツキシマブの有効性と安全性の研究

筋肉痛脳脊髄炎/慢性疲労症候群(ME/CFS)におけるリツキシマブ(遺伝的組換え)の有効性と安全性に関する探索的、プラセボ対照二重盲検、第II相第II相試験

The efficacy and safety of rituximab on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.

調査の概要

詳細な説明

The efficacy and safety of rituximab (genetical recombination), a CD20 antibody, on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Takami Ishizuka, PhD
  • 電話番号:+081-42-341-2711
  • メール:tmc-crso@ncnp.go.jp

研究場所

    • Tokyo
      • Kodaira、Tokyo、日本、187-8551
        • 募集
        • National Center of Neurology and Psychiatry
        • コンタクト:
        • 主任研究者:
          • Tomoko Okamoto, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patients diagnosed with ME/CFS who meet the Canadian criteria by a physician.
  2. Patients with a severity score of 4 or higher on the Performance Status (PS) based ME/CFS severity classification by the Ministry of Health, Labour and Welfare Research Group
  3. Patients who are between 18 and 65 years of age at the time of obtaining written consent
  4. Patients who can be hospitalized (hospitalized from the day before administration and discharged the day after administration) at the time of the first dose of each of the primary and secondary evaluation periods
  5. Patients whose written consent has been obtained

Exclusion Criteria:

  1. Patients with a history of severe hypersensitivity or anaphylactic reactions to components of rituximab or products derived from mouse protein

  2. Patients whose cardiopulmonary function is judged by the treating physician to be not maintained

  3. Patients complaining of fatigue that does not meet the diagnostic criteria for ME/CFS

  4. Patients found to have other medical conditions that may cause symptoms

  5. Patients who are pregnant, lactating, or have a positive pregnancy test (serum human chorionic gonadotropin test) at the time of enrollment

  6. Patients with coexisting or pre-existing malignant tumors (excluding basal cell carcinoma of the skin and cervical dysplasia)

  7. Patients with coexisting or pre-existing severe immune system diseases (excluding autoimmune diseases such as thyroiditis and type 1 diabetes)

  8. Patients with a history of systemic immunosuppressive therapy (e.g., immunoglobulin therapy, azathioprine, cyclosporine, mycophenolate mofetil, etc.) within 1 year, a history of receiving drugs such as monoclonal antibodies acting on the immune system (e.g., anti-CD20 antibody products including rituximab), or a history of comorbidities requiring treatment with immunosuppressive drugs Patients with comorbidities requiring treatment with immunosuppressive agents (excluding treatment with low-dose steroids of 5 mg /day or less)

  9. Patients who have started alternative medicine (reference: acupuncture, moxibustion, and Japanese warm therapy) within 12 weeks prior to the start of treatment with the investigational drug.

  10. Patients with severe endogenous (primary) depression

  11. Patients with a neutrophil count <1.5*103/microliter and platelet count <10.0*104/microliter on blood test

  12. Patients with impaired renal function (serum creatinine level > 1.5 times the upper limit of the reference value at the institution)

  13. Patients with impaired hepatic function (serum bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) levels exceeding 1.5 times the upper limit of the reference value of the institution)

  14. Patients infected with Human Immunodeficiency Virus (HIV)

  15. Patients who test positive for at least one of Hepatitis B surface (HBs) antigen, HBs antibody, Hepatitis B core (HBc) antibody, or Hepatitis C virus (HCV) antibody.

    However, patients who meet the following conditions (1) and (2) may be registered.

    (i) Patients who are positive for HBs or HBc antibodies and whose HBV-DNA quantification is confirmed to be negative (less than detection sensitivity) and for whom appropriate monitoring, etc. can be conducted in accordance with the Guidelines for Hepatitis B Treatment edited by the Japan Society of Hepatology.

    (ii) For patients with positive HCV antibody, when HCV-RNA quantification is negative (less than detection sensitivity)

  16. Patients who do not have the ability to comply with the study protocol

  17. Patients who have participated in other clinical trials or clinical studies (except for observational studies without intervention) within 16 weeks prior to obtaining consent

  18. Other patients who are judged by the investigator or subinvestigator (hereinafter referred to as investigator) to be inappropriate to participate in this clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:プラセボ

Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.

アクティブコンパレータ:リツキシマブ(遺伝的再結合)

Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Improvement rate
時間枠:From Baseline to the end of treatment at 24 weeks

Percentage of cases in which the severity score of ME/CFS based on PS by the MHLW research group improved by 1 or more compared to that before the start of study drug administration (week 0)

From Baseline to the end of treatment at 24 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
MHLW-PSベースのME/CFS重症度スコアが、治療薬による治療開始前(0週目)と比較して、各評価ポイント(改善率)で1つ以上改善した患者の割合。
時間枠:48週目までのベースラインから4週間の間隔で
48週目までのベースラインから4週間の間隔で
MHLW研究グループによるPSに基づくME/CFSの重大度スコアの変化の量は、治療薬による治療の開始前の各評価ポイント(0週目)から
時間枠:48週目までのベースラインから4週間の間隔で
48週目までのベースラインから4週間の間隔で
Proportion of awake time spent in supine position (%),Proportion of awake time spent in sitting position (%)
時間枠:At 4-week intervals from Baseline up to Week 48

Changes in proportions will be aggregated.

At 4-week intervals from Baseline up to Week 48
Duration of standing and activity (hours)
時間枠:At 4-week intervals from Baseline up to Week 48

Changes in time will be aggregated.

At 4-week intervals from Baseline up to Week 48
Fatigue during rest and lying position
時間枠:At 4-week intervals from Baseline up to Week 48

Patients will be asked to report the level of fatigue they feel even while lying down, and changes in their fatigue levels will be aggregated.

At 4-week intervals from Baseline up to Week 48
Records on exertion and Post-Exertional Malaise (PEM)
時間枠:At 4-week intervals from Baseline up to Week 48

Patients will be asked to describe the specific activities they perform and the exhaustion they experience afterward, and a summary table will be created.

At 4-week intervals from Baseline up to Week 48
Assessment of fatigue during physical activity
時間枠:At 4-week intervals from Baseline up to Week 48

Patients will be asked to report the level of fatigue they experience during physical activity in daily life, and changes in fatigue levels will be aggregated.

At 4-week intervals from Baseline up to Week 48
Evaluation based on Fatigue Score
時間枠:At 2-week intervals from Baseline up to Week 48

Patients will be asked to complete the Fatigue Score questionnaire, and changes in the score will be aggregated.

At 2-week intervals from Baseline up to Week 48
SF-36
時間枠:At 12-week intervals from Baseline up to Week 48

Changes in scores obtained from the SF-36 questionnaire will be assessed to evaluate patients' quality of life.

At 12-week intervals from Baseline up to Week 48
COMPASS31
時間枠:At 12-week intervals from Baseline up to Week 48

Changes in scores obtained from the COMPASS31 questionnaire will be assessed to evaluate patients' autonomic symptoms.

At 12-week intervals from Baseline up to Week 48
Pittsburgh Sleep Quality Index (PSQI)
時間枠:At 12-week intervals from Baseline up to Week 48

Changes in scores obtained from the PSQI questionnaire will be assessed to evaluate patients' sleep quality.

At 12-week intervals from Baseline up to Week 48
Pain intensity
時間枠:At 12-week intervals from Baseline up to Week 48

Pain intensity will be assessed using the Visual Analogue Scale (VAS)

At 12-week intervals from Baseline up to Week 48
Grip strength
時間枠:At 12-week intervals from Baseline up to Week 48

Patients' grip strength will be measured, and changes in the measurements will be aggregated.

At 12-week intervals from Baseline up to Week 48
Analysis of the gut microbiota
時間枠:At 24-week intervals from Baseline up to Week 48

samples collected from patients will be analyzed, and the composition of the gut microbiota will be aggregated.

At 24-week intervals from Baseline up to Week 48
Brain imaging evaluation (Magnetic Resonance Imaging (MRI) of the head, Single Photon Emission Computed Tomography (SPECT) of cerebral blood flow)
時間枠:At 24-week intervals from Baseline up to Week 48

Findings from imaging will be aggregated.

At 24-week intervals from Baseline up to Week 48
Immune biomarker analysis (qPCR)
時間枠:At 24-week intervals from Baseline up to Week 48

qPCR will be measured, and changes in their levels will be aggregated.

At 24-week intervals from Baseline up to Week 48
Immune biomarker analysis (anti-autonomic receptor antibody analysis)
時間枠:At 24-week intervals from Baseline up to Week 48

Quantify the level of anti-autonomic receptor antibodies will be measured, and changes in their levels will be aggregated.

At 24-week intervals from Baseline up to Week 48
Immune biomarker analysis (immune cell subfractionation analysis)
時間枠:At 24-week intervals from Baseline up to Week 48

The subsets of immune cells will be measured, and changes in the levels will be aggregated.

At 24-week intervals from Baseline up to Week 48
Metabolome analysis
時間枠:At Baseline

A detailed characterization of the patients' metabolome at baseline will be conducted.

At Baseline
Adverse events
時間枠:From Baseline up to Week 48

The number of adverse events will be aggregated.

From Baseline up to Week 48
Vital signs (body temperature)
時間枠:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48

Summary statistics of vital signs will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
Vital signs (blood pressure)
時間枠:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48

Summary statistics of vital signs will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
Vital signs (pulse rate)
時間枠:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48

Summary statistics of vital signs will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
Serum immunoglobulins (IgG)
時間枠:At 4-week intervals from Baseline up to Week 48

Summary statistics of serum immunoglobulins will be calculated to monitor changes over time.

At 4-week intervals from Baseline up to Week 48
Serum immunoglobulins (IgM)
時間枠:At 4-week intervals from Baseline up to Week 48

Summary statistics of serum immunoglobulins will be calculated to monitor changes over time.

At 4-week intervals from Baseline up to Week 48
Serum immunoglobulins (IgA)
時間枠:At 4-week intervals from Baseline up to Week 48

Summary statistics of serum immunoglobulins will be calculated to monitor changes over time.

At 4-week intervals from Baseline up to Week 48
Rituximab concentration of the blood plasma
時間枠:Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48

Rituximab concentration of the blood plasma

Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48
Blood drug concentration Anti-Drug Antibody (ADA)
時間枠:Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.

Summary statistics of ADA will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.
B cells (CD19/CD20 positive cells) and T cells (CD3/CD4/CD8 positive cells)
時間枠:Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.

Summary statistics of B cells and T cells will be calculated to monitor changes over time.

Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Tomoko Okamoto, MD、National Center of Neurology and Psychiatry

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年4月9日

一次修了 (推定)

2028年5月31日

研究の完了 (推定)

2028年5月31日

試験登録日

最初に提出

2025年4月9日

QC基準を満たした最初の提出物

2025年4月23日

最初の投稿 (実際)

2025年4月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する